In this episode, 2 European HIV experts share their thoughts on some of the most important new antiretroviral therapy insights from HIV research over the past year.Specifically, the faculty discuss findings from real-world and long-term studies of 2-drug oral regimens, the latest on 2-drug long-acting injectable therapy, how 2-drug options fit into rapid start strategies, and other new and emerging innovations in HIV treatment, including the availability of lenacapavir for multidrug-resistant HIV treatment and resumption of islatravir clinical development.Presenters:Jürgen K. Rockstroh, MDProfessor of MedicineUniversity Hospital BonnDepartment of Medicine IBonn, GermanyAlexandra Calmy, MD, FMH, PhDHIV/AIDS Unit DirectorInfectious Diseases DivisionGeneva University HospitalsUniversity of GenevaGeneva, SwitzerlandContent based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare.Link to full program:http://bit.ly/3Hz0jNa Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related